Apomorphine Injection

Apomorphine injection is used to treat ''off'' episodes (times of difficulty moving, walking, and speaking that may happen as medication wears off or at random) in people with advanced Parkinson's disease (PD; a disorder of the nervous system that causes difficulties with movement, muscle control, and balance) who are taking other medications for their condition. Apomorphine injection is in a class of medications called dopamine agonists. It works by acting in place of dopamine, a natural substance produced in the brain that is needed to control movement.

Apomorphine comes as a solution to inject subcutaneously (just under the skin). Apomorphine is usually injected when needed, according to your doctor's directions. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Use apomorphine injection exactly as directed. Do not use more or less of it or use it more often than prescribed by your doctor.

Do not use a second dose of apomorphine injection for treatment of the same "off" episode. Wait at least 2 hours between doses.

Your doctor will give you another medication called trimethobenzamide (Tigan) to take when you begin to use apomorphine injection. This medication will help decrease your chance of developing nausea and vomiting while you are using apomorphine injection, especially during the beginning of treatment. Your doctor will probably tell you to begin taking trimethobenzamide a few days before you begin to use apomorphine injection, and to continue taking it for up to 2 months. You should know that taking trimethobenzamide along with apomorphine injection may increase your risk of drowsiness, dizziness, and falls. However, do not stop taking trimethobenzamide without first talking to your doctor.

Your doctor will probably start you on a low dose of apomorphine injection and gradually increase your dose, not more than once every few days. Ask your doctor what to do if you do not use apomorphine injection for longer than 1 week. Your doctor will probably tell you to restart this medication using a low dose and gradually increase your dose.

Apomorphine solution comes in a glass cartridge to use with an injector pen. Some needles are provided with your pen and additional needles are sold separately. Ask your doctor or pharmacist if you have questions about the type of needle you need. Always use a new, sterile needle for each injection. Never reuse needles, and never let a needle touch any surface except the place where you will inject the medicine. Never store or carry the injector pen with a needle attached. Discard used needles in a puncture-resistant container kept out of reach of children. Talk to your doctor or pharmacist about how to discard the puncture-resistant container.

You will receive your first dose of apomorphine injection in a medical office where your doctor can closely monitor your condition. After that, your doctor may tell you that you can inject apomorphine yourself or have a friend or relative perform the injections. Before you use apomorphine injection yourself the first time, read the written instructions that come with it. Ask your doctor or pharmacist to show you or the person who will be injecting the medication how to inject it.

Be sure you know what numbers on the injector pen show your dose. Your doctor may have told you how many milligrams you need to use, but the pen is marked with milliliters. Ask your doctor or pharmacist if you are not sure how to find your dose on the injector pen.

The apomorphine injector pen is only for use by one person. Do not share your pen with anyone.

Be careful not to get apomorphine injection on your skin or in your eyes. If apomorphine injection does get on your skin or in your eyes, immediately wash your skin or flush your eyes with cold water.

You can inject apomorphine in your stomach area, upper arm, or upper leg. Do not inject into a vein or in an area where the skin is sore, red, bruised, scarred, infected, or abnormal in any way. Use a different spot for each injection, choosing from among the spots you have been told to use. Keep a record of the date and spot of each injection. Do not use the same spot two times in a row.

Always look at your apomorphine solution before you inject it. It should be clear, colorless, and free of particles. Do not use apomorphine if it is cloudy, green, contains particles, or if the expiration date on the carton has passed.

Keep a record of how much apomorphine injection you use each time you receive an injection so that you will know when to replace the medication cartridge.

You may clean your apomorphine injector pen with a damp cloth as needed. Never use strong disinfectants or wash your pen under running water.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before using apomorphine injection,

• tell your doctor and pharmacist if you are allergic to apomorphine, any other medications, sulfites, or any other ingredients in apomorphine injection. Ask your pharmacist for a list of the ingredients.

• tell your doctor if you are taking alosetron (Lotronex), dolasetron (Anzemet), granisetron (Sancuso), ondansetron (Zofran), or palonosetron (Aloxi). Your doctor will probably tell you not to use apomorphine injection if you are taking one of these medications.

• tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: allergy, cough and cold medications; amiodarone (Nexterone, Pacerone); antidepressants; antihistamines; chlorpromazine; disopyramide (Norpace); dofetilide (Tikosyn); erythromycin (E.E.S.); haloperidol (Haldol); medications to treat mental illness, upset stomach, heart disease, high blood pressure, pain, or seizures; metoclopramide (Reglan); moxifloxacin (Avelox); muscle relaxants; other medications for Parkinson's disease; pimozide (Orap); procainamide; prochlorperazine (Compro); promethazine; quinidine (in Nuedexta); sedatives; sildenafil (Viagra, Revatio); sleeping pills; sotalol (Betapace); tadalafil (Cialis); tranquilizers; vardenafil (Levitra); or nitrates such as isosorbide dinitrate (Isordil, in Bidil), isosorbide mononitrate (Monoket), or nitroglycerin (Nitro-Dur, Nitrostat, others). Nitrates come as tablets, sublingual (under the tongue) tablets, sprays, patches, pastes, and ointments. Ask your doctor if you are not sure if any of your medications contain nitrates. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with apomorphine, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.

• you should know that if you take nitroglycerin under your tongue while using apomorphine injection, your blood pressure may decrease and cause dizziness. After taking nitroglycerin tablets under your tongue, you should lie down for at least 45 minutes and avoid standing during this time.

• tell your doctor if you drink alcohol or if you have or have ever had asthma; dizziness; fainting spells; a slow or irregular heartbeat; low blood pressure; low levels of potassium or magnesium in the blood; mental illness; a sleep disorder; a stroke, mini-stroke, or other brain problems; sudden uncontrolled movements and falls; or heart, kidney, or liver disease.

• tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. If you become pregnant while using apomorphine injection, call your doctor.

• if you are having surgery, including dental surgery, tell the doctor or dentist that you are using apomorphine injection.

• you should know that apomorphine injection may make you drowsy. Do not drive a car, operate machinery, or do anything that might put you at risk of getting hurt until you know how this medication affects you.

• you should know that you may suddenly fall asleep during your regular daily activities while you are using apomorphine injection. You may not feel drowsy before you fall asleep. If you suddenly fall asleep while you are doing an everyday activity such as eating, talking, or watching television, call your doctor. Do not drive a car or operate machinery until you talk to your doctor.

• you should not drink alcohol while you are using apomorphine injection. Alcohol can make the side effects from apomorphine injection worse.

• you should know that some people who took medications such as apomorphine injection developed gambling problems or other intense urges or behaviors that were compulsive or unusual for them, such as increased sexual urges or behaviors. There is not enough information to tell whether the people developed these problems because they took the medication or for other reasons. Call your doctor if you have an urge to gamble that is difficult to control, you have intense urges, or you are unable to control your behavior. Tell your family members about this risk so that they can call the doctor even if you do not realize that your gambling or any other intense urges or unusual behaviors have become a problem.

• you should know that apomorphine injection may cause dizziness, lightheadedness, nausea, sweating, and fainting when you get up too quickly from a lying or sitting position. This is more common when you first start using apomorphine injection or following an increase in dose. To avoid this problem, get out of bed or get up from a seated position slowly, resting your feet on the floor for a few minutes before standing up.

Unless your doctor tells you otherwise, continue your normal diet.

This medication is usually used as needed.

• Apomorphine injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

  • nausea

  • vomiting

  • constipation

  • diarrhea

  • headache

  • yawning

  • runny nose

  • weakness

  • arm, leg, or back pain

  • pain or difficulty in urination

  • soreness, redness, pain, bruising, swelling, or itching in the place where you injected apomorphine

• Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately or get emergency medical treatment:

  • rash; hives; itching; swelling of the face, throat, tongue, lips, or eyes; difficulty breathing and swallowing; shortness of breath;cough; or hoarseness

  • fainting

  • fast or pounding heartbeat

  • chest pain

  • swelling of the hands, feet, ankles, or lower legs

  • bruising

  • sudden uncontrollable movements

  • falling down

  • hallucinations (seeing things or hearing voices that do not exist), aggressive behavior, agitation, feeling like people are against you, or disorganized thoughts

  • depression

  • fever

  • confusion

  • painful erection that does not go away

• Some laboratory animals that were given apomorphine injection developed eye disease. It is not known if apomorphine injection increases the risk of eye disease in humans. Talk to your doctor about the risks of using this medication.

• Apomorphine may cause other side effects. Call your doctor if you have any unusual problems while using this medication.

• If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the cartridge it came in and out of reach of children. Store it in the carrying case at room temperature and away from light, excess heat and moisture (not in the bathroom).

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include the following:

• nausea

• fainting

• dizziness

• blurred vision

• slow heartbeat

• abnormal behavior

• hallucinations

• sudden uncontrollable movements

Keep all appointments with your doctor.

Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug	Interaction
Moxifloxacin	Moxifloxacin The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Moxifloxacin.
Repaglinide	Repaglinide The metabolism of Repaglinide can be decreased when combined with Apomorphine.
Montelukast	Montelukast The metabolism of Apomorphine can be decreased when combined with Montelukast.
Delavirdine	Delavirdine The metabolism of Apomorphine can be decreased when combined with Delavirdine.
Nevirapine	Nevirapine The metabolism of Apomorphine can be increased when combined with Nevirapine.
Atorvastatin	Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Apomorphine.
Dolasetron	Dolasetron The risk or severity of hypotension can be increased when Apomorphine is combined with Dolasetron.
Anagrelide	Anagrelide The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Anagrelide.
Candesartan	Candesartan The metabolism of Candesartan can be decreased when combined with Apomorphine.
Cilostazol	Cilostazol The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Cilostazol.
Clopidogrel	Clopidogrel The metabolism of Apomorphine can be decreased when combined with Clopidogrel.
Diphenoxylate	Diphenoxylate The risk or severity of adverse effects can be increased when Apomorphine is combined with Diphenoxylate.
Erythromycin and Sulfisoxazole	Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Erythromycin.
Fenofibrate	Fenofibrate The metabolism of Apomorphine can be decreased when combined with Fenofibrate.
Guanfacine	Guanfacine The risk or severity of adverse effects can be increased when Apomorphine is combined with Guanfacine.
Methylergonovine	Methylergonovine The therapeutic efficacy of Apomorphine can be decreased when used in combination with Methylergometrine.
Naratriptan	Naratriptan The risk or severity of adverse effects can be increased when Apomorphine is combined with Naratriptan.
Paregoric	Paregoric The risk or severity of adverse effects can be increased when Morphine is combined with Apomorphine.
Penbutolol	Penbutolol The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Acebutolol.
Pentazocine	Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Apomorphine.
Reserpine	Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Apomorphine.
Rizatriptan	Rizatriptan The risk or severity of adverse effects can be increased when Apomorphine is combined with Rizatriptan.
Sumatriptan	Sumatriptan The risk or severity of adverse effects can be increased when Sumatriptan is combined with Apomorphine.
Tacrolimus	Tacrolimus The metabolism of Tacrolimus can be decreased when combined with Apomorphine.
Tizanidine	Tizanidine The risk or severity of adverse effects can be increased when Tizanidine is combined with Apomorphine.
Triamcinolone	Triamcinolone The metabolism of Apomorphine can be increased when combined with Triamcinolone.
Zolmitriptan	Zolmitriptan The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Apomorphine.
Famotidine Injection	Famotidine Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Famotidine.
Fluconazole Injection	Fluconazole Injection The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Apomorphine.
Foscarnet Injection	Foscarnet Injection The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Apomorphine.
Hydromorphone Injection	Hydromorphone Injection The risk or severity of adverse effects can be increased when Hydromorphone is combined with Apomorphine.
Levofloxacin Injection	Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Levofloxacin.
Meperidine Injection	Meperidine Injection The risk or severity of adverse effects can be increased when Meperidine is combined with Apomorphine.
Metoclopramide Injection	Metoclopramide Injection The risk or severity of sedation can be increased when Metoclopramide is combined with Apomorphine.
Metronidazole Injection	Metronidazole Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Metronidazole.
Morphine Injection	Morphine Injection The risk or severity of adverse effects can be increased when Morphine is combined with Apomorphine.
Zidovudine Injection	Zidovudine Injection The metabolism of Apomorphine can be decreased when combined with Zidovudine.
Altretamine	Altretamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Apomorphine.
Cyclosporine	Cyclosporine The metabolism of Apomorphine can be decreased when combined with Cyclosporine.
Ondansetron	Ondansetron The risk or severity of adverse effects can be increased when Ondansetron is combined with Apomorphine.
Granisetron	Granisetron The risk or severity of hypotension can be increased when Apomorphine is combined with Granisetron.
Torsemide	Torsemide The metabolism of Torasemide can be decreased when combined with Apomorphine.
Olanzapine	Olanzapine The therapeutic efficacy of Apomorphine can be decreased when used in combination with Olanzapine.
Alosetron	Alosetron The risk or severity of hypotension can be increased when Apomorphine is combined with Alosetron.
Dofetilide	Dofetilide The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Dofetilide.
Entacapone	Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Apomorphine.
Eprosartan	Eprosartan The risk or severity of adverse effects can be increased when Apomorphine is combined with Eprosartan.
Hydroxychloroquine	Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Hydroxychloroquine.
Oxcarbazepine	Oxcarbazepine The risk or severity of adverse effects can be increased when Apomorphine is combined with Oxcarbazepine.
Telmisartan	Telmisartan The risk or severity of adverse effects can be increased when Apomorphine is combined with Telmisartan.
Zaleplon	Zaleplon The risk or severity of adverse effects can be increased when Apomorphine is combined with Zaleplon.
Anakinra	Anakinra The metabolism of Apomorphine can be increased when combined with Anakinra.
Desloratadine	Desloratadine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Desloratadine.
Linezolid	Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Apomorphine.
Trimipramine	Trimipramine The risk or severity of adverse effects can be increased when Apomorphine is combined with Trimipramine.
Etanercept Injection	Etanercept Injection The metabolism of Apomorphine can be increased when combined with Etanercept.
Glycopyrrolate	Glycopyrrolate Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.
Modafinil	Modafinil The metabolism of Apomorphine can be increased when combined with Modafinil.
Perindopril	Perindopril The risk or severity of adverse effects can be increased when Apomorphine is combined with Perindopril.
Sirolimus	Sirolimus The metabolism of Sirolimus can be decreased when combined with Apomorphine.
Dutasteride	Dutasteride The metabolism of Dutasteride can be decreased when combined with Apomorphine.
Eplerenone	Eplerenone The risk or severity of adverse effects can be increased when Apomorphine is combined with Eplerenone.
Escitalopram	Escitalopram The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Escitalopram.
Olmesartan	Olmesartan The risk or severity of adverse effects can be increased when Apomorphine is combined with Olmesartan.
Zonisamide	Zonisamide The risk or severity of adverse effects can be increased when Apomorphine is combined with Zonisamide.
Adalimumab Injection	Adalimumab Injection The metabolism of Apomorphine can be increased when combined with Adalimumab.
Aripiprazole	Aripiprazole The risk or severity of adverse effects can be decreased when Apomorphine is combined with Aripiprazole.
Atomoxetine	Atomoxetine The risk or severity of adverse effects can be increased when Atomoxetine is combined with Apomorphine.
Dexmethylphenidate	Dexmethylphenidate The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Apomorphine.
Atazanavir	Atazanavir The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Atazanavir.
Almotriptan	Almotriptan The risk or severity of adverse effects can be increased when Apomorphine is combined with Almotriptan.
Eletriptan	Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Apomorphine.
Mefloquine	Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Apomorphine.
Rosuvastatin	Rosuvastatin The metabolism of Rosuvastatin can be decreased when combined with Apomorphine.
Vardenafil	Vardenafil The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Vardenafil.
Alfuzosin	Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Apomorphine.
Aprepitant	Aprepitant The metabolism of Apomorphine can be decreased when combined with Aprepitant.
Memantine	Memantine The metabolism of Apomorphine can be decreased when combined with Memantine.
Tegaserod	Tegaserod The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Tegaserod.
Tadalafil	Tadalafil The metabolism of Tadalafil can be decreased when combined with Apomorphine.
Frovatriptan	Frovatriptan The risk or severity of adverse effects can be increased when Apomorphine is combined with Frovatriptan.
Gemifloxacin	Gemifloxacin The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Gemifloxacin.
Progesterone	Progesterone The metabolism of Apomorphine can be decreased when combined with Progesterone.
Infliximab Injection	Infliximab Injection The metabolism of Apomorphine can be increased when combined with Infliximab.
Protriptyline	Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Apomorphine.
Rifaximin	Rifaximin The metabolism of Apomorphine can be increased when combined with Rifaximin.
Duloxetine	Duloxetine The risk or severity of orthostatic hypotension and syncope can be increased when Apomorphine is combined with Duloxetine.
Norethindrone	Norethindrone The metabolism of Norethisterone can be decreased when combined with Apomorphine.
Trospium	Trospium Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Trospium.
Bosentan	Bosentan Apomorphine may increase the hypotensive activities of Bosentan.
Erlotinib	Erlotinib The metabolism of Erlotinib can be decreased when combined with Apomorphine.
Eszopiclone	Eszopiclone The risk or severity of CNS depression can be increased when Apomorphine is combined with Eszopiclone.
Solifenacin	Solifenacin Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.
Voriconazole	Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Apomorphine.
Dextroamphetamine	Dextroamphetamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Apomorphine.
Sodium Oxybate	Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Apomorphine.
Ibandronate	Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Apomorphine.
Isocarboxazid	Isocarboxazid The risk or severity of adverse effects can be increased when Apomorphine is combined with Isocarboxazid.
Ramelteon	Ramelteon The risk or severity of adverse effects can be increased when Apomorphine is combined with Ramelteon.
Darifenacin	Darifenacin Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.
Fentanyl	Fentanyl The risk or severity of adverse effects can be increased when Apomorphine is combined with Fentanyl.
Pregabalin	Pregabalin The therapeutic efficacy of Apomorphine can be increased when used in combination with Pregabalin.
Deferasirox	Deferasirox The metabolism of Apomorphine can be decreased when combined with Deferasirox.
Felbamate	Felbamate The risk or severity of adverse effects can be increased when Apomorphine is combined with Felbamate.
Ranolazine	Ranolazine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ranolazine.
Abatacept Injection	Abatacept Injection The metabolism of Apomorphine can be increased when combined with Abatacept.
Rasagiline	Rasagiline The risk or severity of adverse effects can be increased when Apomorphine is combined with Rasagiline.
Imatinib	Imatinib The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Imatinib.
Sitagliptin	Sitagliptin The metabolism of Sitagliptin can be decreased when combined with Apomorphine.
Gefitinib	Gefitinib The metabolism of Apomorphine can be decreased when combined with Gefitinib.
Albuterol	Albuterol The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Salbutamol.
Paliperidone	Paliperidone The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Paliperidone.
Bortezomib	Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Apomorphine.
Clofarabine Injection	Clofarabine Injection The risk or severity of adverse effects can be increased when Clofarabine is combined with Apomorphine.
Oxaliplatin Injection	Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Oxaliplatin.
Posaconazole	Posaconazole The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Posaconazole.
Primaquine	Primaquine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Primaquine.
Aliskiren	Aliskiren The risk or severity of adverse effects can be increased when Apomorphine is combined with Aliskiren.
Dimenhydrinate	Dimenhydrinate The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Dimenhydrinate.
Lisdexamfetamine	Lisdexamfetamine The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Lisdexamfetamine.
Nabilone	Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Apomorphine.
Vorinostat	Vorinostat The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Vorinostat.
Sorafenib	Sorafenib The metabolism of Apomorphine can be decreased when combined with Sorafenib.
Sunitinib	Sunitinib The metabolism of Sunitinib can be decreased when combined with Apomorphine.
Dronabinol	Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Apomorphine.
Lapatinib	Lapatinib The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Lapatinib.
Levocetirizine	Levocetirizine The risk or severity of adverse effects can be increased when Apomorphine is combined with Levocetirizine.
Dasatinib	Dasatinib The metabolism of Dasatinib can be decreased when combined with Apomorphine.
Mexiletine	Mexiletine The metabolism of Apomorphine can be decreased when combined with Mexiletine.
Armodafinil	Armodafinil The metabolism of Apomorphine can be increased when combined with Armodafinil.
Temsirolimus	Temsirolimus The metabolism of Apomorphine can be decreased when combined with Temsirolimus.
Nilotinib	Nilotinib The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Nilotinib.
Toremifene	Toremifene The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Toremifene.
Bexarotene	Bexarotene The metabolism of Apomorphine can be decreased when combined with Bexarotene.
Budesonide	Budesonide The metabolism of Apomorphine can be increased when combined with Budesonide.
Chloramphenicol Injection	Chloramphenicol Injection The metabolism of Apomorphine can be decreased when combined with Chloramphenicol.
OnabotulinumtoxinA Injection	OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Apomorphine.
RimabotulinumtoxinB Injection	RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Apomorphine.
Arsenic Trioxide Injection	Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Arsenic trioxide.
Desvenlafaxine	Desvenlafaxine The risk or severity of adverse effects can be increased when Apomorphine is combined with Desvenlafaxine.
Nebivolol	Nebivolol The risk or severity of adverse effects can be increased when Apomorphine is combined with Nebivolol.
Tretinoin	Tretinoin The metabolism of Tretinoin can be decreased when combined with Apomorphine.
Flecainide	Flecainide The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Flecainide.
Certolizumab Injection	Certolizumab Injection The metabolism of Apomorphine can be increased when combined with Certolizumab pegol.
Irinotecan Injection	Irinotecan Injection The metabolism of Irinotecan can be decreased when combined with Apomorphine.
Praziquantel	Praziquantel The metabolism of Praziquantel can be decreased when combined with Apomorphine.
Rufinamide	Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Apomorphine.
Midazolam	Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Apomorphine.
Naltrexone Injection	Naltrexone Injection The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Apomorphine.
Eltrombopag	Eltrombopag The metabolism of Apomorphine can be decreased when combined with Eltrombopag.
Milnacipran	Milnacipran The risk or severity of adverse effects can be increased when Apomorphine is combined with Milnacipran.
Fesoterodine	Fesoterodine Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
Degarelix Injection	Degarelix Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Degarelix.
Betaxolol	Betaxolol The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Betaxolol.
Iloperidone	Iloperidone The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Iloperidone.
Prasugrel	Prasugrel The metabolism of Prasugrel can be decreased when combined with Apomorphine.
Lacosamide	Lacosamide The risk or severity of adverse effects can be increased when Apomorphine is combined with Lacosamide.
Dronedarone	Dronedarone The metabolism of Dronedarone can be decreased when combined with Apomorphine.
AbobotulinumtoxinA Injection	AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Apomorphine.
Palonosetron Injection	Palonosetron Injection The risk or severity of hypotension can be increased when Palonosetron is combined with Apomorphine.
Saxagliptin	Saxagliptin The metabolism of Saxagliptin can be decreased when combined with Apomorphine.
Telavancin Injection	Telavancin Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Telavancin.
Romidepsin Injection	Romidepsin Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Romidepsin.
Tapentadol	Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Apomorphine.
Golimumab Injection	Golimumab Injection The metabolism of Apomorphine can be increased when combined with Golimumab.
Pazopanib	Pazopanib The metabolism of Pazopanib can be decreased when combined with Apomorphine.
Asenapine	Asenapine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Asenapine.
Vigabatrin	Vigabatrin The risk or severity of adverse effects can be increased when Apomorphine is combined with Vigabatrin.
Pitavastatin	Pitavastatin The metabolism of Pitavastatin can be decreased when combined with Apomorphine.
Levonorgestrel	Levonorgestrel The metabolism of Apomorphine can be decreased when combined with Levonorgestrel.
Oxymorphone	Oxymorphone The risk or severity of adverse effects can be increased when Apomorphine is combined with Oxymorphone.
Tocilizumab Injection	Tocilizumab Injection The metabolism of Apomorphine can be increased when combined with Tocilizumab.
Eribulin Injection	Eribulin Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Eribulin.
IncobotulinumtoxinA Injection	IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Apomorphine.
Cabazitaxel Injection	Cabazitaxel Injection The metabolism of Cabazitaxel can be decreased when combined with Apomorphine.
Lurasidone	Lurasidone The therapeutic efficacy of Apomorphine can be decreased when used in combination with Lurasidone.
Vilazodone	Vilazodone The risk or severity of adverse effects can be increased when Apomorphine is combined with Vilazodone.
Denileukin Diftitox Injection	Denileukin Diftitox Injection The risk or severity of adverse effects can be increased when Aldesleukin is combined with Apomorphine.
Terbutaline Injection	Terbutaline Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Terbutaline.
Azilsartan	Azilsartan The risk or severity of adverse effects can be increased when Apomorphine is combined with Azilsartan medoxomil.
Rilpivirine	Rilpivirine The metabolism of Rilpivirine can be decreased when combined with Apomorphine.
Cyclophosphamide Injection	Cyclophosphamide Injection The metabolism of Apomorphine can be decreased when combined with Cyclophosphamide.
Abiraterone	Abiraterone The metabolism of Apomorphine can be decreased when combined with Abiraterone.
Triptorelin Injection	Triptorelin Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Triptorelin.
Rivaroxaban	Rivaroxaban The metabolism of Rivaroxaban can be decreased when combined with Apomorphine.
Vandetanib	Vandetanib The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Vandetanib.
Clobazam	Clobazam The risk or severity of adverse effects can be increased when Clobazam is combined with Apomorphine.
Vemurafenib	Vemurafenib The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Vemurafenib.
Vismodegib	Vismodegib The metabolism of Apomorphine can be decreased when combined with Vismodegib.
Ivacaftor	Ivacaftor The metabolism of Ivacaftor can be decreased when combined with Apomorphine.
Axitinib	Axitinib The metabolism of Axitinib can be decreased when combined with Apomorphine.
Crizotinib	Crizotinib The metabolism of Crizotinib can be decreased when combined with Apomorphine.
Cabergoline	Cabergoline The risk or severity of adverse effects can be decreased when Cabergoline is combined with Apomorphine.
Ambrisentan	Ambrisentan The metabolism of Ambrisentan can be decreased when combined with Apomorphine.
Ezogabine	Ezogabine The risk or severity of adverse effects can be increased when Apomorphine is combined with Tiagabine.
Iloprost	Iloprost The risk or severity of adverse effects can be increased when Apomorphine is combined with Iloprost.
Enzalutamide	Enzalutamide The metabolism of Apomorphine can be decreased when combined with Enzalutamide.
Mirabegron	Mirabegron The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Mirabegron.
Regorafenib	Regorafenib The metabolism of Apomorphine can be decreased when combined with Regorafenib.
Bosutinib	Bosutinib The metabolism of Apomorphine can be decreased when combined with Bosutinib.
Teriflunomide	Teriflunomide The metabolism of Apomorphine can be decreased when combined with Teriflunomide.
Cabozantinib (thyroid cancer)	Cabozantinib (thyroid cancer) The metabolism of Apomorphine can be decreased when combined with Cabozantinib.
Bedaquiline	Bedaquiline The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Bedaquiline.
Ponatinib	Ponatinib The metabolism of Ponatinib can be decreased when combined with Apomorphine.
Pomalidomide	Pomalidomide The risk or severity of adverse effects can be increased when Apomorphine is combined with Pomalidomide.
Ado-trastuzumab Emtansine Injection	Ado-trastuzumab Emtansine Injection The metabolism of Trastuzumab emtansine can be decreased when combined with Apomorphine.
Apixaban	Apixaban The metabolism of Apixaban can be decreased when combined with Apomorphine.
Canagliflozin	Canagliflozin The risk or severity of adverse effects can be increased when Apomorphine is combined with Canagliflozin.
Methazolamide	Methazolamide The risk or severity of adverse effects can be increased when Methazolamide is combined with Apomorphine.
Dabrafenib	Dabrafenib The metabolism of Dabrafenib can be decreased when combined with Apomorphine.
Ospemifene	Ospemifene The metabolism of Ospemifene can be decreased when combined with Apomorphine.
Trametinib	Trametinib The metabolism of Apomorphine can be decreased when combined with Trametinib.
Levomilnacipran	Levomilnacipran The risk or severity of adverse effects can be increased when Apomorphine is combined with Levomilnacipran.
Vortioxetine	Vortioxetine The risk or severity of hypotension can be increased when Apomorphine is combined with Vortioxetine.
Perampanel	Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Apomorphine.
Ibrutinib	Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Apomorphine.
Avanafil	Avanafil The risk or severity of hypotension can be increased when Avanafil is combined with Apomorphine.
Ketorolac Injection	Ketorolac Injection The metabolism of Apomorphine can be decreased when combined with Ketorolac.
Obinutuzumab Injection	Obinutuzumab Injection The risk or severity of adverse effects can be increased when Apomorphine is combined with Obinutuzumab.
Dapagliflozin	Dapagliflozin The risk or severity of adverse effects can be increased when Apomorphine is combined with Dapagliflozin.
Apremilast	Apremilast The metabolism of Apomorphine can be increased when combined with Apremilast.
Ceritinib	Ceritinib The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ceritinib.
Siltuximab Injection	Siltuximab Injection The metabolism of Apomorphine can be increased when combined with Siltuximab.
Eslicarbazepine	Eslicarbazepine The risk or severity of adverse effects can be increased when Apomorphine is combined with Eslicarbazepine.
Testosterone Injection	Testosterone Injection The metabolism of Apomorphine can be decreased when combined with Testosterone.
Empagliflozin	Empagliflozin The risk or severity of adverse effects can be increased when Apomorphine is combined with Empagliflozin.
Hydrocodone	Hydrocodone Hydrocodone may increase the central nervous system depressant (CNS depressant) activities of Apomorphine.
Suvorexant	Suvorexant Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Olaparib	Olaparib The metabolism of Olaparib can be decreased when combined with Apomorphine.
Methamphetamine	Methamphetamine The risk or severity of adverse effects can be increased when Apomorphine is combined with Metamfetamine.
Tasimelteon	Tasimelteon The risk or severity of adverse effects can be increased when Apomorphine is combined with Tasimelteon.
Riociguat	Riociguat The metabolism of Riociguat can be decreased when combined with Apomorphine.
Secukinumab Injection	Secukinumab Injection The metabolism of Apomorphine can be increased when combined with Secukinumab.
Risperidone Injection	Risperidone Injection Apomorphine may increase the hypotensive activities of Risperidone.
Lenvatinib	Lenvatinib The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Lenvatinib.
Panobinostat	Panobinostat The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Panobinostat.
Dinutuximab Injection	Dinutuximab Injection The risk or severity of adverse effects can be increased when Apomorphine is combined with Dinutuximab.
Haloperidol Injection	Haloperidol Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Haloperidol.
Ivabradine	Ivabradine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ivabradine.
Amiloride	Amiloride The risk or severity of adverse effects can be increased when Amiloride is combined with Apomorphine.
Macitentan	Macitentan Apomorphine may increase the hypotensive activities of Macitentan.
Flibanserin	Flibanserin The risk or severity of adverse effects can be increased when Apomorphine is combined with Flibanserin.
Daclatasvir	Daclatasvir The metabolism of Daclatasvir can be decreased when combined with Apomorphine.
Brexpiprazole	Brexpiprazole The risk or severity of adverse effects can be decreased when Apomorphine is combined with Brexpiprazole.
Ziprasidone Injection	Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ziprasidone.
Cariprazine	Cariprazine The therapeutic efficacy of Apomorphine can be decreased when used in combination with Cariprazine.
Eluxadoline	Eluxadoline The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Eluxadoline.
Rifapentine	Rifapentine The metabolism of Apomorphine can be increased when combined with Rifapentine.
Amphotericin B Liposomal Injection	Amphotericin B Liposomal Injection The risk or severity of adverse effects can be increased when Amphotericin B is combined with Apomorphine.
Dexamethasone Injection	Dexamethasone Injection The metabolism of Apomorphine can be increased when combined with Dexamethasone.
Brivaracetam Injection	Brivaracetam Injection The risk or severity of adverse effects can be increased when Apomorphine is combined with Brivaracetam.
Cobicistat	Cobicistat The metabolism of Apomorphine can be decreased when combined with Cobicistat.
Selexipag	Selexipag The metabolism of Selexipag can be decreased when combined with Apomorphine.
Pimavanserin	Pimavanserin The therapeutic efficacy of Apomorphine can be decreased when used in combination with Pimavanserin.
Diphenhydramine Injection	Diphenhydramine Injection The risk or severity of adverse effects can be increased when Apomorphine is combined with Diphenhydramine.
Furosemide Injection	Furosemide Injection The risk or severity of adverse effects can be increased when Furosemide is combined with Apomorphine.
Rucaparib	Rucaparib The metabolism of Apomorphine can be decreased when combined with Rucaparib.
Ribociclib	Ribociclib The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ribociclib.
Brigatinib	Brigatinib The metabolism of Brigatinib can be decreased when combined with Apomorphine.
Doxepin (Insomnia)	Doxepin (Insomnia) The risk or severity of adverse effects can be increased when Apomorphine is combined with Doxepin.
Deutetrabenazine	Deutetrabenazine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Deutetrabenazine.
Valbenazine	Valbenazine The metabolism of Valbenazine can be decreased when combined with Apomorphine.
Deflazacort	Deflazacort The metabolism of Apomorphine can be increased when combined with Deflazacort.
Safinamide	Safinamide The risk or severity of adverse effects can be increased when Apomorphine is combined with Safinamide.
Midostaurin	Midostaurin The metabolism of Apomorphine can be increased when combined with Midostaurin.
Enasidenib	Enasidenib The metabolism of Apomorphine can be decreased when combined with Enasidenib.
Copanlisib Injection	Copanlisib Injection The metabolism of Copanlisib can be decreased when combined with Apomorphine.
Delafloxacin	Delafloxacin The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Delafloxacin.
Acalabrutinib	Acalabrutinib The metabolism of Apomorphine can be decreased when combined with Acalabrutinib.
Letermovir	Letermovir The metabolism of Apomorphine can be decreased when combined with Letermovir.
Tetrabenazine	Tetrabenazine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Tetrabenazine.
Buprenorphine Injection	Buprenorphine Injection Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Apalutamide	Apalutamide The metabolism of Apalutamide can be decreased when combined with Apomorphine.
Fostamatinib	Fostamatinib The risk or severity of hypotension can be increased when Fostamatinib is combined with Apomorphine.
Avatrombopag	Avatrombopag The metabolism of Apomorphine can be increased when combined with Avatrombopag.
Lofexidine	Lofexidine The therapeutic efficacy of Apomorphine can be increased when used in combination with Lofexidine.
Eliglustat	Eliglustat The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Eliglustat.
Encorafenib	Encorafenib The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Encorafenib.
Ivosidenib	Ivosidenib The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ivosidenib.
Elagolix	Elagolix The metabolism of Elagolix can be decreased when combined with Apomorphine.
Doravirine	Doravirine The metabolism of Doravirine can be decreased when combined with Apomorphine.
Cannabidiol	Cannabidiol The risk or severity of adverse effects can be increased when Cannabidiol is combined with Apomorphine.
Stiripentol	Stiripentol The risk or severity of adverse effects can be increased when Apomorphine is combined with Stiripentol.
Gilteritinib	Gilteritinib The therapeutic efficacy of Apomorphine can be decreased when used in combination with Gilteritinib.
Glasdegib	Glasdegib The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Glasdegib.
Lorlatinib	Lorlatinib The metabolism of Lorlatinib can be decreased when combined with Apomorphine.
Paclitaxel (with albumin) Injection	Paclitaxel (with albumin) Injection The metabolism of Paclitaxel can be decreased when combined with Apomorphine.
Rifamycin	Rifamycin The metabolism of Apomorphine can be decreased when combined with Rifamycin.
Emapalumab-lzsg Injection	Emapalumab-lzsg Injection The metabolism of Apomorphine can be increased when combined with Emapalumab.
Alpelisib	Alpelisib The metabolism of Apomorphine can be decreased when combined with Alpelisib.
Brexanolone Injection	Brexanolone Injection The risk or severity of adverse effects can be increased when Apomorphine is combined with Brexanolone.
Solriamfetol	Solriamfetol The risk or severity of adverse effects can be increased when Apomorphine is combined with Solriamfetol.
Triclabendazole	Triclabendazole The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Triclabendazole.
Entrectinib	Entrectinib The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Entrectinib.
Istradefylline	Istradefylline The metabolism of Istradefylline can be decreased when combined with Apomorphine.
Pitolisant	Pitolisant Apomorphine may increase the QTc-prolonging activities of Pitolisant.
Lefamulin	Lefamulin Lefamulin may increase the QTc-prolonging activities of Apomorphine.
Phenytoin Injection	Phenytoin Injection The metabolism of Apomorphine can be decreased when combined with Phenytoin.
Fosphenytoin Injection	Fosphenytoin Injection The metabolism of Fosphenytoin can be decreased when combined with Apomorphine.
Zanubrutinib	Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Apomorphine.
Voxelotor	Voxelotor The metabolism of Voxelotor can be decreased when combined with Apomorphine.
Lumateperone	Lumateperone The therapeutic efficacy of Apomorphine can be decreased when used in combination with Lumateperone.
Lasmiditan	Lasmiditan The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Lasmiditan.
Cenobamate	Cenobamate The serum concentration of Apomorphine can be decreased when it is combined with Cenobamate.
Ozanimod	Ozanimod The metabolism of Ozanimod can be decreased when combined with Apomorphine.
Selumetinib	Selumetinib The metabolism of Selumetinib can be decreased when combined with Apomorphine.
Tucatinib	Tucatinib The metabolism of Tucatinib can be decreased when combined with Apomorphine.
Selpercatinib	Selpercatinib The serum concentration of Apomorphine can be increased when it is combined with Selpercatinib.
Lemborexant	Lemborexant The serum concentration of Lemborexant can be decreased when it is combined with Apomorphine.
Fenfluramine	Fenfluramine The risk or severity of serotonin syndrome can be increased when Fenfluramine is combined with Apomorphine.
Fostemsavir	Fostemsavir The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Fostemsavir.
Octreotide	Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Apomorphine.
Pralsetinib	Pralsetinib The metabolism of Apomorphine can be decreased when combined with Pralsetinib.
Opicapone	Opicapone The metabolism of Apomorphine can be decreased when combined with Opicapone.
Relugolix	Relugolix The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Relugolix.
Viloxazine	Viloxazine The risk or severity of adverse effects can be increased when Apomorphine is combined with Viloxazine.
Theophylline	Theophylline The metabolism of Apomorphine can be decreased when combined with Theophylline.
Mefenamic Acid	Mefenamic Acid The metabolism of Apomorphine can be decreased when combined with Mefenamic acid.
Naproxen	Naproxen The metabolism of Naproxen can be decreased when combined with Apomorphine.
Trazodone	Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Apomorphine.
Phenobarbital	Phenobarbital The metabolism of Apomorphine can be increased when combined with Phenobarbital.
Metaxalone	Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Apomorphine.
Levorphanol	Levorphanol The risk or severity of adverse effects can be increased when Apomorphine is combined with Levorphanol.
Primidone	Primidone Primidone may increase the hypotensive activities of Apomorphine.
Methsuximide	Methsuximide The risk or severity of adverse effects can be increased when Apomorphine is combined with Methsuximide.
Diethylpropion	Diethylpropion The risk or severity of adverse effects can be increased when Apomorphine is combined with Diethylpropion.
Chlorpromazine	Chlorpromazine The therapeutic efficacy of Apomorphine can be decreased when used in combination with Chlorpromazine.
Diazepam	Diazepam The risk or severity of adverse effects can be increased when Apomorphine is combined with Diazepam.
Oxazepam	Oxazepam The risk or severity of adverse effects can be increased when Apomorphine is combined with Oxazepam.
Flurazepam	Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Apomorphine.
Clorazepate	Clorazepate The risk or severity of adverse effects can be increased when Clorazepic acid is combined with Apomorphine.
Lorazepam	Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Apomorphine.
Phenoxybenzamine	Phenoxybenzamine The risk or severity of adverse effects can be increased when Apomorphine is combined with Phenoxybenzamine.
Amantadine	Amantadine The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Amantadine.
Codeine	Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Apomorphine.
Meprobamate	Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Apomorphine.
Chlordiazepoxide	Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Apomorphine.
Bromocriptine	Bromocriptine The risk or severity of adverse effects can be decreased when Apomorphine is combined with Bromocriptine.
Tranylcypromine	Tranylcypromine The risk or severity of adverse effects can be increased when Apomorphine is combined with Tranylcypromine.
Phenelzine	Phenelzine The risk or severity of adverse effects can be increased when Apomorphine is combined with Phenelzine.
Procarbazine	Procarbazine The risk or severity of adverse effects can be increased when Apomorphine is combined with Procarbazine.
Ergoloid Mesylates	Ergoloid Mesylates The risk or severity of adverse effects can be decreased when Apomorphine is combined with Ergoloid mesylate.
Minocycline	Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Apomorphine.
Prochlorperazine	Prochlorperazine The therapeutic efficacy of Apomorphine can be decreased when used in combination with Prochlorperazine.
Thioridazine	Thioridazine The therapeutic efficacy of Thioridazine can be decreased when used in combination with Apomorphine.
Trifluoperazine	Trifluoperazine The therapeutic efficacy of Apomorphine can be decreased when used in combination with Trifluoperazine.
Dapsone	Dapsone The metabolism of Apomorphine can be decreased when combined with Dapsone.
Sulfadiazine	Sulfadiazine The metabolism of Apomorphine can be decreased when combined with Sulfadiazine.
Oxycodone	Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Apomorphine.
Methadone	Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Apomorphine.
Oxybutynin	Oxybutynin Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.
Benztropine	Benztropine Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.
Maprotiline	Maprotiline The risk or severity of adverse effects can be increased when Apomorphine is combined with Maprotiline.
Ibuprofen	Ibuprofen The metabolism of Ibuprofen can be decreased when combined with Apomorphine.
Trihexyphenidyl	Trihexyphenidyl Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.
Orphenadrine	Orphenadrine Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Perphenazine	Perphenazine The therapeutic efficacy of Apomorphine can be decreased when used in combination with Perphenazine.
Fluphenazine	Fluphenazine The therapeutic efficacy of Apomorphine can be decreased when used in combination with Fluphenazine.
Phentermine	Phentermine The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Apomorphine.
Methylphenidate	Methylphenidate The risk or severity of adverse effects can be increased when Methylphenidate is combined with Apomorphine.
Amoxapine	Amoxapine The risk or severity of adverse effects can be increased when Amoxapine is combined with Apomorphine.
Hydrocortisone	Hydrocortisone The metabolism of Hydrocortisone can be increased when combined with Apomorphine.
Doxorubicin	Doxorubicin The metabolism of Apomorphine can be decreased when combined with Doxorubicin.
Carbamazepine	Carbamazepine The metabolism of Apomorphine can be decreased when combined with Carbamazepine.
Molindone	Molindone The therapeutic efficacy of Apomorphine can be decreased when used in combination with Molindone.
Methyldopa	Methyldopa The risk or severity of adverse effects can be increased when Apomorphine is combined with Methyldopa.
Clonidine	Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Apomorphine.
Prazosin	Prazosin The risk or severity of adverse effects can be increased when Apomorphine is combined with Prazosin.
Hydralazine	Hydralazine The risk or severity of adverse effects can be increased when Apomorphine is combined with Hydralazine.
Cimetidine	Cimetidine The metabolism of Apomorphine can be decreased when combined with Cimetidine.
Warfarin	Warfarin The metabolism of Warfarin can be decreased when combined with Apomorphine.
Clonazepam	Clonazepam The risk or severity of adverse effects can be increased when Apomorphine is combined with Clonazepam.
Loperamide	Loperamide The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Loperamide.
Promethazine	Promethazine The risk or severity of adverse effects can be increased when Apomorphine is combined with Promethazine.
Daunorubicin	Daunorubicin The metabolism of Apomorphine can be increased when combined with Daunorubicin.
Griseofulvin	Griseofulvin The metabolism of Apomorphine can be increased when combined with Griseofulvin.
Digoxin	Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Apomorphine.
Loxapine	Loxapine The therapeutic efficacy of Apomorphine can be decreased when used in combination with Loxapine.
Chloroquine	Chloroquine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Chloroquine.
Quinine	Quinine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Quinine.
Ethosuximide	Ethosuximide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Apomorphine.
Triamterene	Triamterene The risk or severity of adverse effects can be increased when Triamterene is combined with Apomorphine.
Sulfinpyrazone	Sulfinpyrazone The metabolism of Apomorphine can be decreased when combined with Sulfinpyrazone.
Chlorothiazide	Chlorothiazide The risk or severity of adverse effects can be increased when Apomorphine is combined with Chlorothiazide.
Chlorthalidone	Chlorthalidone The risk or severity of adverse effects can be increased when Apomorphine is combined with Chlorthalidone.
Metolazone	Metolazone The risk or severity of adverse effects can be increased when Apomorphine is combined with Metolazone.
Clindamycin Injection	Clindamycin Injection The metabolism of Clindamycin can be decreased when combined with Apomorphine.
Secobarbital	Secobarbital The metabolism of Apomorphine can be increased when combined with Secobarbital.
Desipramine	Desipramine The risk or severity of adverse effects can be increased when Apomorphine is combined with Desipramine.
Amitriptyline	Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Apomorphine.
Imipramine	Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Apomorphine.
Probenecid	Probenecid The metabolism of Apomorphine can be increased when combined with Probenecid.
Quinidine	Quinidine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Quinidine.
Procainamide	Procainamide The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Procainamide.
Isoniazid	Isoniazid The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Isoniazid.
Rifampin	Rifampin The metabolism of Apomorphine can be increased when combined with Rifampicin.
Disopyramide	Disopyramide The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Disopyramide.
Valproic Acid	Valproic Acid The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Valproic acid.
Tamoxifen	Tamoxifen The metabolism of Apomorphine can be decreased when combined with Tamoxifen.
Butabarbital	Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Apomorphine.
Levothyroxine	Levothyroxine The metabolism of Apomorphine can be decreased when combined with Levothyroxine.
Methimazole	Methimazole The metabolism of Apomorphine can be decreased when combined with Methimazole.
Tolbutamide	Tolbutamide The metabolism of Apomorphine can be decreased when combined with Tolbutamide.
Dextromethorphan	Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Apomorphine.
Cyclobenzaprine	Cyclobenzaprine The risk or severity of CNS depression can be increased when Apomorphine is combined with Cyclobenzaprine.
Baclofen	Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Apomorphine.
Doxylamine	Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Apomorphine.
Cyproheptadine	Cyproheptadine The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Apomorphine.
Clemastine	Clemastine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Clemastine.
Chlorpheniramine	Chlorpheniramine The risk or severity of adverse effects can be increased when Apomorphine is combined with Chlorpheniramine.
Brompheniramine	Brompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Apomorphine.
Meclizine	Meclizine The risk or severity of adverse effects can be increased when Apomorphine is combined with Meclizine.
Methyclothiazide	Methyclothiazide The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Apomorphine.
Hydrochlorothiazide	Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Hydrochlorothiazide.
Dantrolene	Dantrolene The risk or severity of adverse effects can be increased when Apomorphine is combined with Dantrolene.
Chlorzoxazone	Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Apomorphine.
Carisoprodol	Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Apomorphine.
Methocarbamol	Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Apomorphine.
Disulfiram	Disulfiram The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Disulfiram.
Propranolol (Cardiovascular)	Propranolol (Cardiovascular) The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Propranolol.
Minoxidil	Minoxidil The risk or severity of adverse effects can be increased when Apomorphine is combined with Minoxidil.
Pseudoephedrine	Pseudoephedrine The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Pseudoephedrine.
Nortriptyline	Nortriptyline The risk or severity of adverse effects can be increased when Nortriptyline is combined with Apomorphine.
Spironolactone	Spironolactone The metabolism of Apomorphine can be decreased when combined with Spironolactone.
Amphotericin B Injection	Amphotericin B Injection The risk or severity of adverse effects can be increased when Amphotericin B is combined with Apomorphine.
Nadolol	Nadolol The risk or severity of adverse effects can be increased when Apomorphine is combined with Nadolol.
Butorphanol Injection	Butorphanol Injection The risk or severity of adverse effects can be increased when Butorphanol is combined with Apomorphine.
Nalbuphine Injection	Nalbuphine Injection The risk or severity of adverse effects can be increased when Apomorphine is combined with Nalbuphine.
Oxytocin Injection	Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Apomorphine.
Trimethobenzamide	Trimethobenzamide The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Apomorphine.
Flavoxate	Flavoxate Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
Papaverine	Papaverine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Papaverine.
Fluorouracil Injection	Fluorouracil Injection The metabolism of Fluorouracil can be decreased when combined with Apomorphine.
Colchicine	Colchicine The metabolism of Apomorphine can be decreased when combined with Colchicine.
Acetazolamide	Acetazolamide The risk or severity of adverse effects can be increased when Apomorphine is combined with Acetazolamide.
Ketoconazole	Ketoconazole The metabolism of Ketoconazole can be decreased when combined with Apomorphine.
Pyrantel	Pyrantel The risk or severity of adverse effects can be increased when Apomorphine is combined with Pyrantel.
Thiotepa Injection	Thiotepa Injection The metabolism of Apomorphine can be decreased when combined with Thiotepa.
Vincristine Injection	Vincristine Injection The metabolism of Apomorphine can be decreased when combined with Vincristine.
Captopril	Captopril The risk or severity of adverse effects can be increased when Apomorphine is combined with Captopril.
Dipyridamole	Dipyridamole The risk or severity of adverse effects can be increased when Apomorphine is combined with Dipyridamole.
Isoxsuprine	Isoxsuprine The risk or severity of adverse effects can be increased when Apomorphine is combined with Isoxsuprine.
Ethacrynic Acid	Ethacrynic Acid The risk or severity of adverse effects can be increased when Apomorphine is combined with Etacrynic acid.
Metoprolol	Metoprolol The risk or severity of adverse effects can be increased when Apomorphine is combined with Metoprolol.
Hydroxyzine	Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Apomorphine.
Thiothixene	Thiothixene The therapeutic efficacy of Apomorphine can be decreased when used in combination with Thiothixene.
Alprazolam	Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Apomorphine.
Temazepam	Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Apomorphine.
Triazolam	Triazolam The risk or severity of adverse effects can be increased when Apomorphine is combined with Triazolam.
Dicyclomine	Dicyclomine Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
Hyoscyamine	Hyoscyamine Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Propantheline	Propantheline Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
Trimethoprim	Trimethoprim The metabolism of Apomorphine can be decreased when combined with Trimethoprim.
Diltiazem	Diltiazem The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Diltiazem.
Nifedipine	Nifedipine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Nifedipine.
Timolol	Timolol The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Timolol.
Verapamil	Verapamil The metabolism of Apomorphine can be decreased when combined with Verapamil.
Atenolol	Atenolol The risk or severity of adverse effects can be increased when Apomorphine is combined with Atenolol.
Pindolol	Pindolol The risk or severity of adverse effects can be increased when Apomorphine is combined with Pindolol.
Cisplatin Injection	Cisplatin Injection The metabolism of Apomorphine can be decreased when combined with Cisplatin.
Piroxicam	Piroxicam The metabolism of Apomorphine can be decreased when combined with Piroxicam.
Bumetanide	Bumetanide The risk or severity of adverse effects can be increased when Apomorphine is combined with Bumetanide.
Etoposide	Etoposide The metabolism of Etoposide can be decreased when combined with Apomorphine.
Glyburide	Glyburide The metabolism of Glyburide can be decreased when combined with Apomorphine.
Indapamide	Indapamide The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Indapamide.
Pentoxifylline	Pentoxifylline The risk or severity of hypotension can be increased when Pentoxifylline is combined with Apomorphine.
Pentamidine Injection	Pentamidine Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Pentamidine.
Labetalol	Labetalol The risk or severity of adverse effects can be increased when Apomorphine is combined with Labetalol.
Leuprolide Injection	Leuprolide Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Leuprolide.
Gemfibrozil	Gemfibrozil The metabolism of Apomorphine can be decreased when combined with Gemfibrozil.
Guanabenz	Guanabenz Apomorphine may increase the hypotensive activities of Guanabenz.
Ketoprofen	Ketoprofen The metabolism of Apomorphine can be decreased when combined with Ketoprofen.
Pimozide	Pimozide The therapeutic efficacy of Pimozide can be decreased when used in combination with Apomorphine.
Enalapril	Enalapril The risk or severity of adverse effects can be increased when Apomorphine is combined with Enalapril.
Amiodarone	Amiodarone The metabolism of Amiodarone can be decreased when combined with Apomorphine.
Buspirone	Buspirone The risk or severity of serotonin syndrome can be increased when Buspirone is combined with Apomorphine.
Lovastatin	Lovastatin The metabolism of Apomorphine can be decreased when combined with Lovastatin.
Ciprofloxacin	Ciprofloxacin The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ciprofloxacin.
Diclofenac	Diclofenac The metabolism of Apomorphine can be decreased when combined with Diclofenac.
Fluoxetine	Fluoxetine The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Fluoxetine.
Nimodipine	Nimodipine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Nimodipine.
Clozapine	Clozapine The therapeutic efficacy of Apomorphine can be decreased when used in combination with Clozapine.
Estazolam	Estazolam The risk or severity of adverse effects can be increased when Apomorphine is combined with Estazolam.
Ofloxacin	Ofloxacin The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ofloxacin.
Clarithromycin	Clarithromycin The metabolism of Clarithromycin can be decreased when combined with Apomorphine.
Benazepril	Benazepril The risk or severity of adverse effects can be increased when Apomorphine is combined with Benazepril.
Felodipine	Felodipine The metabolism of Felodipine can be decreased when combined with Apomorphine.
Fosinopril	Fosinopril The risk or severity of adverse effects can be increased when Apomorphine is combined with Fosinopril.
Quinapril	Quinapril The risk or severity of adverse effects can be increased when Apomorphine is combined with Quinapril.
Ramipril	Ramipril The risk or severity of adverse effects can be increased when Apomorphine is combined with Ramipril.
Simvastatin	Simvastatin The metabolism of Apomorphine can be decreased when combined with Simvastatin.
Amlodipine	Amlodipine The risk or severity of adverse effects can be increased when Apomorphine is combined with Amlodipine.
Teniposide Injection	Teniposide Injection The metabolism of Apomorphine can be decreased when combined with Teniposide.
Itraconazole	Itraconazole The metabolism of Itraconazole can be decreased when combined with Apomorphine.
Lisinopril	Lisinopril The risk or severity of adverse effects can be increased when Apomorphine is combined with Lisinopril.
Rifabutin	Rifabutin The metabolism of Apomorphine can be increased when combined with Rifabutin.
Sotalol	Sotalol The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Sotalol.
Bisoprolol	Bisoprolol The risk or severity of adverse effects can be increased when Apomorphine is combined with Bisoprolol.
Zolpidem	Zolpidem Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Doxazosin	Doxazosin The risk or severity of adverse effects can be increased when Apomorphine is combined with Doxazosin.
Terazosin	Terazosin The risk or severity of adverse effects can be increased when Apomorphine is combined with Terazosin.
Isradipine	Isradipine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Isradipine.
Omeprazole	Omeprazole The metabolism of Apomorphine can be decreased when combined with Omeprazole.
Cisapride	Cisapride The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Cisapride.
Gabapentin	Gabapentin The risk or severity of adverse effects can be increased when Apomorphine is combined with Gabapentin.
Fluvastatin	Fluvastatin The metabolism of Apomorphine can be decreased when combined with Fluvastatin.
Venlafaxine	Venlafaxine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Apomorphine.
Fluvoxamine	Fluvoxamine The risk or severity of adverse effects can be increased when Apomorphine is combined with Fluvoxamine.
Nefazodone	Nefazodone The risk or severity of adverse effects can be increased when Apomorphine is combined with Nefazodone.
Lamotrigine	Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Apomorphine.
Losartan	Losartan The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Losartan.
Tramadol	Tramadol The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Apomorphine.
Moexipril	Moexipril The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Moexipril.
Lansoprazole	Lansoprazole The metabolism of Apomorphine can be decreased when combined with Lansoprazole.
Ifosfamide Injection	Ifosfamide Injection The metabolism of Ifosfamide can be decreased when combined with Apomorphine.
Nicardipine	Nicardipine Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.
Bupropion	Bupropion The risk or severity of adverse effects can be increased when Bupropion is combined with Apomorphine.
Ticlopidine	Ticlopidine The metabolism of Apomorphine can be decreased when combined with Ticlopidine.
Saquinavir	Saquinavir The metabolism of Saquinavir can be decreased when combined with Apomorphine.
Nisoldipine	Nisoldipine The risk or severity of adverse effects can be increased when Apomorphine is combined with Nisoldipine.
Riluzole	Riluzole The risk or severity of adverse effects can be increased when Apomorphine is combined with Riluzole.
Amifostine Injection	Amifostine Injection The risk or severity of adverse effects can be increased when Apomorphine is combined with Amifostine.
Anastrozole	Anastrozole The metabolism of Anastrozole can be decreased when combined with Apomorphine.
Indinavir	Indinavir The metabolism of Apomorphine can be decreased when combined with Indinavir.
Ritonavir	Ritonavir The metabolism of Apomorphine can be decreased when combined with Ritonavir.
Docetaxel Injection	Docetaxel Injection The metabolism of Docetaxel can be decreased when combined with Apomorphine.
Clomipramine	Clomipramine The risk or severity of adverse effects can be increased when Apomorphine is combined with Clomipramine.
Zafirlukast	Zafirlukast The metabolism of Apomorphine can be decreased when combined with Zafirlukast.
Mirtazapine	Mirtazapine Apomorphine may increase the serotonergic activities of Mirtazapine.
Trandolapril	Trandolapril The risk or severity of adverse effects can be increased when Apomorphine is combined with Trandolapril.
Topiramate	Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Apomorphine.
Valsartan	Valsartan The risk or severity of adverse effects can be increased when Apomorphine is combined with Valsartan.
Pramipexole	Pramipexole Pramipexole may increase the sedative activities of Apomorphine.
Donepezil	Donepezil The risk or severity of adverse effects can be increased when Apomorphine is combined with Donepezil.
Nelfinavir	Nelfinavir The metabolism of Apomorphine can be decreased when combined with Nelfinavir.
Azithromycin	Azithromycin The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Azithromycin.
Loratadine	Loratadine The metabolism of Apomorphine can be decreased when combined with Loratadine.
Carvedilol	Carvedilol The risk or severity of adverse effects can be increased when Apomorphine is combined with Carvedilol.
Nilutamide	Nilutamide The metabolism of Apomorphine can be decreased when combined with Nilutamide.
Flutamide	Flutamide The metabolism of Apomorphine can be decreased when combined with Flutamide.
Selegiline	Selegiline The risk or severity of adverse effects can be increased when Apomorphine is combined with Selegiline.
Sertraline	Sertraline The risk or severity of adverse effects can be increased when Apomorphine is combined with Sertraline.
Propafenone	Propafenone The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Propafenone.
Raloxifene	Raloxifene The metabolism of Apomorphine can be decreased when combined with Raloxifene.
Irbesartan	Irbesartan The metabolism of Irbesartan can be decreased when combined with Apomorphine.
Tamsulosin	Tamsulosin The risk or severity of adverse effects can be increased when Tamsulosin is combined with Apomorphine.
Ropinirole	Ropinirole Ropinirole may increase the sedative activities of Apomorphine.
Finasteride	Finasteride The metabolism of Finasteride can be decreased when combined with Apomorphine.
Quetiapine	Quetiapine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Quetiapine.
Cetirizine	Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Apomorphine.
Paroxetine	Paroxetine The risk or severity of adverse effects can be increased when Apomorphine is combined with Paroxetine.
Tolcapone	Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Apomorphine.
Citalopram	Citalopram The risk or severity of adverse effects can be increased when Apomorphine is combined with Citalopram.
Efavirenz	Efavirenz The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Efavirenz.
Sildenafil	Sildenafil The metabolism of Apomorphine can be decreased when combined with Sildenafil.
Pioglitazone	Pioglitazone The metabolism of Apomorphine can be decreased when combined with Pioglitazone.
Celecoxib	Celecoxib The metabolism of Apomorphine can be decreased when combined with Celecoxib.
Rosiglitazone	Rosiglitazone The metabolism of Apomorphine can be decreased when combined with Rosiglitazone.
Tolterodine	Tolterodine Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.
Thalidomide	Thalidomide Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Nateglinide	Nateglinide The metabolism of Nateglinide can be decreased when combined with Apomorphine.
Galantamine	Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Apomorphine.
Levetiracetam	Levetiracetam The risk or severity of adverse effects can be increased when Apomorphine is combined with Levetiracetam.
Rabeprazole	Rabeprazole The metabolism of Apomorphine can be decreased when combined with Rabeprazole.
Terbinafine	Terbinafine The metabolism of Apomorphine can be decreased when combined with Terbinafine.